Laureate Announces Second Manufacturing Agreement with Cytheris

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for immune T-cell recovery, for utilization in continuing international clinical research at the moment being carried out for HIV, HCV and cancer treatment. Terms and conditions of the contract were not revealed.

Recombinant human Interleukin-7 (r-hIL-7) is a growth-stimulating factor for immune T-cell recovery and its stimulation. Clinical trials carried out on more than 75 participants in Europe, the U.S. and Canada have offered to take the potential of r-hIL-7 to restore and secure CD4+ and CD8+ T-cells.

“We are happy that Cytheris has chosen us again as their contract manufacturing organization, to produce IL-7 in the maintenance of their more extensive clinical research affair. This is a review to our prosperous cooperation with our customers and our effort to reach the absolute satisfaction in the capability to satisfy their manufacturing demands,” said Robert J. Broeze, Ph.D., President & CEO of Laureate. “We will cooperate with the Cytheris team very closely and assist them to arrange the greatest potential  property of their IL-7 development and production pattern.”

“As we are advanced to large-scale manufacturing of our IL-7 biotherapeutic, we are satisfied to prolong our stable cooperating relationship with Laureate Pharma,” said Jamie Garner, DVM, President and CEO of Cytheris. “With Laureate’s shown ability in the prosperous transfer of processing technology, we are striving to go on to cooperate together in the process scale-up, engineering and clinical material manufacturing of IL-7 for our continuing clinical research exploring multiple indications.”

About Laureate Pharma, Inc.

Laureate Pharma is a full-function facility of biopharmaceutical development and protein manufacturing based in Princeton, New Jersey. Laureate Pharma proposes superior services in bioprocessing that speed up new products from development through production. Laureate ensures a wide assortment of specific services from processing design and development to large-scale cGMP manufacturing, clearance, aseptic filling, testing, validation, analytical services, and regulatory maintenance. Laureate is oriented on 2 active divisions of the biopharmaceutical branches: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc.

See also  Laureate Pharma Agreement with Alopexx Pharmaceuticals

About Cytheris SA

Cytheris SA is an individually run clinical-phase biopharmaceutical facility oriented on trial and development of new therapies for immune stimulation. These medications are subject to rebuilding and improving the immune systems of patients having the following diagnosis: cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). The company performs its functions from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.